FOLFOXIRI Plus Panitumumab for Left-sided RAS-wild-type Metastatic Colorectal Cancer.

Authors

Howard S Hochster, Patrick J Blatchford, Stacey Stein, Jill Lacy, Anup Kasi, Patrick M Boland, Philp Gold, Aaron J Scott, Paul Oberstein, Michael Cusnir, Kate Rouse, Karen Mallalieu, Anwaar Saeed, AGICC Group

Published in

The oncologist. Aug 18, 2026. Epub Aug 18, 2026.

Abstract

Colorectal cancer (CRC) can be effectively treated with fluoropyrimidine chemotherapy doublets. The triplet chemotherapy program, FOLFOXIRI, is more effective than a doublet in randomized trials. We combined this triplet with the anti-EGFR antibody, panitumumab, as first line therapy in the appropriately targeted population: left-sided, RAS wild-type metastatic colorectal cancer.
A multicenter trial was conducted with the AGICC (Academic GI Cancer Consortium) group. Patients with stage IV or unresectable, left-sided, RAS wild-type CRC were eligible if they had measurable disease, adequate organ function and PS 0-1. Consented patients were treated with modified FOLFOXIRI and panitumumab every 2 weeks until progression or toxicity. CT scans were performed every 8 weeks. Primary endpoint was Response Rate by RECIST v1, with expectation of a RR ≥ 85%.
29 patients were enrolled and 27 were treated. 430 cycles were given including 7 pts with the maximum 24 cycles (median 18, range 3-24). Best response included 2 CR, 18 PR and 6 SD (RR 74%). One patient progressed at time of first assessment. Grade 3+ toxicity included neutropenia, diarrhea, rash, hypomagnesemia and hypokalemia, similar to prior reports. No patient had grade 5 toxicity. Median PFS was 17.0 months and OS was not reached but exceeds 36 months.
In this small US multicenter study, utilizing FOLFOXIRI with an anti-EGFR antibody for appropriately selected patients, we note among the highest response rate and PFS reported for stage IV colon cancer.

PMID:
42610703
Bibliographic data and abstract were imported from PubMed on 18 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.